ArticleJMA journal2025
Clinical Factors Associated with Body-weight Reduction Induced by Semaglutide 1.0 mg Weekly in Patients with Type 2 Diabetes Mellitus.
Article in JMA journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: We examined the clinical factors associated with a decrease in weight induced by weekly semaglutide in patients with type 2 diabetes mellitus (T2DM). Methods: Patients with T2DM who visited the Diabetes Care Center of Jinnouchi Hospital between June 2020 and October 2023 and were treated with semaglutide, 1.0 mg weekly, in addition to their ongoing medications were retrospectively registered. We measured body weight both before weekly administration of 1.0 mg semaglutide and 180 days after treatment and calculated the change in weight. Results: A total of 96 patients with T2DM were enrolled, with a mean body weight of 87.2 ± 17.1 kg and mean HbA1c of 7.3 ± 1.7% at baseline. The greater response group, defined as having 1.0 mg weekly semaglutide treatment-related weight reduction of more than 7.0%, comprised 23 patients (24.0%). Weekly 1.0 mg semaglutide treatment for 180 days significantly reduced body weight (-3.1 ± 4.8 kg, p < 0.001) and glycated hemoglobin (-0.39% ± 1.23%, p = 0.003). Multivariable logistic regression analysis found that pretreatment high-density lipoprotein (HDL)-cholesterol levels per 1.0 mg/dL (odds ratio [OR] 1.05; 95% confidence interval [CI] 1.01-1.09, p = 0.02) were independently and significantly associated with greater weight reduction after weekly 1.0 mg semaglutide treatment, while a switch from other glucagon-like peptide-1 receptor agonists (OR 0.31; 95% CI 0.11-0.87; p = 0.03) was independently and significantly associated with lesser weight reduction after weekly 1.0 mg semaglutide treatment. In receiver-operator characteristic analysis, the cutoff value of pretreatment HDL-cholesterol levels for the presence of greater response in weight reduction was 46 mg/dL (sensitivity 61%, specificity 62%; p = 0.03). Conclusions: Pretreatment HDL-cholesterol levels serve as important information for weekly treatment with 1.0 mg semaglutide in patients with T2DM and expectation of weight reduction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.